isochroman-7-ol | 1391209-22-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: isochroman-7-ol
• 英文别名: 3,4-dihydro-1H-isochromen-7-ol
• CAS: 1391209-22-5
• 化学式: C₉H₁₀O₂
• 分子量: 150.177
• InChiKey: GYGRPMTVIVLWOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  isochroman-7-ol 、 叔丁基二甲基氯硅烷 在 咪唑 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以100%的产率得到tert-butyl(isochroman-7-yloxy)dimethylsilane
  参考文献：
  名称：

  巯基自由基促进铁与分子氧对苄基sp 3 C–H键的铁催化选择性氧化†

  摘要：

  已开发出一种无配体的铁催化方法，该方法使用噻吩基作为助催化剂，通过分子氧（1 atm）氧化苄基sp 3 C–H键。该转化提供了从容易获得的相应的胺，醚和烷烃容易地获得酰胺，酯和酮的途径。它具有高区域选择性，温和的氧化条件和出色的官能团相容性，为复杂分子的位点选择性官能化提供了很好的机会。初步的机理研究表明，该反应可能不会经历苄基阳离子中间途径，并且产物中的羰基氧原子可能源自分子氧。

  DOI：

  10.1039/c9cc06584a
• 作为产物：
  描述：

  2-(4-甲基羰基氧基苯基)-1-乙醇 、 氯甲基甲基醚 在 N,N-二异丙基乙胺 、 三氟甲磺酸三甲基硅酯 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 26.0h， 以50%的产率得到isochroman-7-yl acetate
  参考文献：
  名称：

  巯基自由基促进铁与分子氧对苄基sp 3 C–H键的铁催化选择性氧化†

  摘要：

  已开发出一种无配体的铁催化方法，该方法使用噻吩基作为助催化剂，通过分子氧（1 atm）氧化苄基sp 3 C–H键。该转化提供了从容易获得的相应的胺，醚和烷烃容易地获得酰胺，酯和酮的途径。它具有高区域选择性，温和的氧化条件和出色的官能团相容性，为复杂分子的位点选择性官能化提供了很好的机会。初步的机理研究表明，该反应可能不会经历苄基阳离子中间途径，并且产物中的羰基氧原子可能源自分子氧。

  DOI：

  10.1039/c9cc06584a

文献信息

• 6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
  申请人：BAO JIANMING

  公开号：US20170183342A1

  公开（公告）日：2017-06-29

  The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及6,7-二氢-5H-吡咯[3,4-b]吡啶-5-酮化合物，这些化合物是M4毒蕈碱乙酰胆碱受体的变构调节剂。本发明还涉及在本申请中描述的化合物在潜在治疗或预防神经和精神障碍和疾病中的应用，其中涉及M4毒蕈碱乙酰胆碱受体。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及M4毒蕈碱乙酰胆碱受体的疾病的应用。
• 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
  申请人：Bao Jianming

  公开号：US10329289B2

  公开（公告）日：2019-06-25

  The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及 6,7-二氢-5H-吡咯并[3,4-b]吡啶-5-酮化合物，这些化合物是 M4 肌 肉碱乙酰胆碱受体的异构调节剂。本发明还涉及本文所述化合物在潜在治疗或预防涉及 M4 肌卡因乙酰胆碱受体的神经和精神障碍及疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及 M4 蕈样乙酰胆碱受体的此类疾病中的用途。
• 6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10351564B2

  公开（公告）日：2019-07-16

  The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及 6,7-二氢-5H-吡咯并[3,4-b]吡啶-5-酮化合物，这些化合物是 M4 肌 肉碱乙酰胆碱受体的异构调节剂。本发明还涉及本文所述化合物在潜在治疗或预防涉及 M4 肌卡因乙酰胆碱受体的神经和精神障碍及疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及 M4 蕈样乙酰胆碱受体的此类疾病中的用途。
• [EN] 6, 7-DIHYDRO-5H-PYRROLO [3, 4-B] PYRIDIN-5-ONEALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR<br/>[FR] MODULATEURS ALLOSTÉRIQUES 6,7-DIHYDRO -5H-PYRROLO[3,4-B]PYRIDIN-5-ONE DU RÉCEPTEUR DE L'ACÉTYLCHOLINE MUSCARINIQUE M4
  申请人：MERCK SHARP & DOHME

  公开号：WO2017107087A1

  公开（公告）日：2017-06-29

  The present invention is directed to 6, 7-dihydro-5H-pyrrolo [3, 4-b] pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
• [EN] 6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR<br/>[FR] MODULATEURS ALLOSTÉRIQUES 6,7-DIHYDRO-5H-PYRROLO[3,4-B] PYRIDINE-5-ONE DU RÉCEPTEUR DE L'ACÉTYLCHOLINE MUSCARINIQUE M4
  申请人：MERCK SHARP & DOHME

  公开号：WO2017112719A1

  公开（公告）日：2017-06-29

  The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved. Formula (I).